Xilio Therapeutics Statistics
Share Statistics
Xilio Therapeutics has 43.96M shares outstanding. The number of shares has increased by 59.66% in one year.
| Shares Outstanding | 43.96M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 19.07% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 20.53M |
| Failed to Deliver (FTD) Shares | 2.42K |
| FTD / Avg. Volume | 1.02% |
Short Selling Information
The latest short interest is 396.08K, so 0.9% of the outstanding shares have been sold short.
| Short Interest | 396.08K |
| Short % of Shares Out | 0.9% |
| Short % of Float | 1.93% |
| Short Ratio (days to cover) | 1.36 |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is -1.84.
| PE Ratio | -0.2 |
| Forward PE | -1.84 |
| PS Ratio | 0 |
| Forward PS | 1.3 |
| PB Ratio | 0.41 |
| P/FCF Ratio | -218.83 |
| PEG Ratio | n/a |
Enterprise Valuation
Xilio Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.02, with a Debt / Equity ratio of 0.25.
| Current Ratio | 3.02 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.25 |
| Total Debt / Capitalization | 19.97 |
| Cash Flow / Debt | -7.47 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.07% and return on capital (ROIC) is -163.89%.
| Return on Equity (ROE) | -2.07% |
| Return on Assets (ROA) | -1.25% |
| Return on Capital (ROIC) | -163.89% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.05M |
| Employee Count | 73 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 38.03% in the last 52 weeks. The beta is -0.2, so Xilio Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.2 |
| 52-Week Price Change | 38.03% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 0.97 |
| Relative Strength Index (RSI) | 45.42 |
| Average Volume (20 Days) | 237.58K |
Income Statement
In the last 12 months, Xilio Therapeutics had revenue of $0 and earned -$76.40M in profits. Earnings per share was $-2.78.
| Revenue | 0 |
| Gross Profit | -1.90M |
| Operating Income | -79.13M |
| Net Income | -76.40M |
| EBITDA | -73.80M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.78 |
Balance Sheet
The company has $44.70M in cash and $11.46M in debt, giving a net cash position of $33.25M.
| Cash & Cash Equivalents | 44.70M |
| Total Debt | 11.46M |
| Net Cash | 33.25M |
| Retained Earnings | -325.51M |
| Total Assets | 74.66M |
| Working Capital | 25.29M |
Cash Flow
In the last 12 months, operating cash flow was -$68.62M and capital expenditures -$486.00K, giving a free cash flow of -$69.11K.
| Operating Cash Flow | -68.62M |
| Capital Expenditures | -486.00K |
| Free Cash Flow | -69.11K |
| FCF Per Share | 0 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -283.67% |
| FCF Yield | -0.16% |
Analyst Forecast
The average price target for XLO is $4, which is 308.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 308.2% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -8.78 |
| Piotroski F-Score | 4 |